NEK6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15168715	0.65	4/20
SCHEMBL16418191	0.65	4/20
SCHEMBL3503253	1.00	3/20
SCHEMBL3503624	1.00	3/20
SCHEMBL3503626	1.00	3/20
SCHEMBL15377692	0.91	3/20
SCHEMBL3504073	0.89	3/20
SCHEMBL3503601	0.88	3/20
SCHEMBL3503591	0.87	3/20
SCHEMBL3504626	0.85	3/20
SCHEMBL3504873	0.85	3/20
SCHEMBL3503538	0.85	3/20
Potassium Ion (SCHEMBL3503567)	0.85	3/20
SCHEMBL3502388	0.84	3/20
Onvansertib (SCHEMBL1228019)	0.84	3/20
SCHEMBL3503742	0.84	3/20
SCHEMBL3504256	0.83	3/20
SCHEMBL3504604	0.82	3/20
SCHEMBL3504328	0.82	3/20
SCHEMBL13225440	0.82	3/20

Clinical trials — most relevant to NEK6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Implementing Patients´ Competence in Oral Breast Cancer Therapy	nan	UNKNOWN
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm	nan	UNKNOWN
Genetics of Neonatal Encephalopathy and Related Disorders	nan	RECRUITING
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NEK6 binder may also engage these)

Protein	Name	Similarity
P59895	—	1.000	P59895 →
Q9ES70	—	1.000	Q9ES70 →
A2BD05	—	1.000	A2BD05 →
D3ZBE5	—	0.988	D3ZBE5 →
Q9ES74	—	0.985	Q9ES74 →
NEK7	Serine/threonine-protein kinase Nek7	0.982	landscape →
G5EFM9	—	0.980	G5EFM9 →
MAP2K6	Dual specificity mitogen-activated protein kinase kinase 6	0.972	landscape →
Q9DGE0	—	0.972	Q9DGE0 →
P70236	—	0.966	P70236 →
Q5E9X2	—	0.966	Q5E9X2 →
Q4WSF6	—	0.965	Q4WSF6 →
Q965G5	—	0.965	Q965G5 →
A1IVT7	—	0.964	A1IVT7 →
MAP2K3	Dual specificity mitogen-activated protein kinase kinase 3	0.964	landscape →
Q4W6D3	—	0.964	Q4W6D3 →
G1XJZ4	—	0.964	G1XJZ4 →
Q8NJT7	—	0.964	Q8NJT7 →
TSSK1B	Testis-specific serine/threonine-protein kinase 1	0.964	landscape →
O88697	—	0.964	O88697 →
Q63844	—	0.964	Q63844 →
O09110	—	0.963	O09110 →
Q4PC06	—	0.963	Q4PC06 →
Q8TGA9	—	0.963	Q8TGA9 →
G5EDF7	—	0.962	G5EDF7 →
Q09892	—	0.961	Q09892 →
HCK	Tyrosine-protein kinase HCK	0.961	landscape →
A3EZ55	—	0.961	A3EZ55 →
Q6C4M9	—	0.960	Q6C4M9 →
MAPK8	Mitogen-activated protein kinase 8	0.960	landscape →